Evaluating SHR-3792 Injection for Advanced Solid Tumors
Official title: A Phase Ⅰ, Open Label, Multicenter Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-3792 in Patients With Advanced Solid Tumors
Run by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · NCT06907628 · Data updated 2026-11-12
This study is testing a new injection called SHR-3792 to see if it can safely help people with advanced solid tumors feel better and how much of it they should take.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 150 (estimated) |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. Industry-sponsored |
| Locations | 1 site (Jinan, Shandong) |
| Status | Recruiting |
| Started | April 2, 2025 |
| Main results expected | February 2027 |
| Study ends | February 2027 |
| Registry record updated | April 25, 2025 |
| Trial ID | NCT06907628 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include patients with unresectable recurrent or metastatic solid tumors who have a life expectancy of at least three months.
✕Probably not a fit
Patients with active central nervous system metastases or those with other serious health conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of SHR-3792 injection as a monotherapy for patients suffering from advanced solid tumors. The study will also explore appropriate dosing for this treatment. Participants will be monitored for their response to the injection and any potential side effects throughout the trial. The trial is designed for patients with unresectable recurrent or metastatic solid tumors who meet specific eligibility criteria.
Why it matters
Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with advanced solid tumors.
How similar studies have gone: While this approach is being explored in this trial, similar studies have shown promise in evaluating new treatments for advanced solid tumors.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Subjects with ability to understand and voluntarily agree to participate by giving written informed consent form for the study. 2. Patients with unresectable recurrent or metastatic solid tumors. 3. There is at least one lesion that could be measured. 4. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 or 1. 5. Adequate organ functions as defined. 6. Life expectancy ≥ 3 months. Exclusion Criteria: 1. Patients with known active central nervous system (CNS) metastases. 2. Subjects with other malignancy in five years before the first dose. 3. Patients with tumor-related pain that cannot be controlled as determined. 4. Patients with serious cardiovascular and cerebrovascular diseases. 5. Uncontrollable third-space effusion, such as pleural effusion, pericardial effusion or peritoneal effusion. 6. Patients with severe infections. 7. History of immunodeficiency. 8. History of autoimmune diseases. 9. Active infection. 10. Pregnant or nursing women. 11. Known history of serious allergic reactions to the investigational product or its main ingredients.
Where it's running
-
Shandong First Medical University Affiliated Cancer Hospital
Jinan, Shandong, China Recruiting
Study contacts
- Study coordinator: Fangfang Peng
- Email: fangfang.peng.fp5@hengrui.com
- Phone: +86-0518-81220121
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
AK157D1 injection for advanced solid tumors
A first-in-human Phase 1 study tests AK157D1 injection in adults with unresectable advanced solid tumors to see if it is safe and tolerable and to get early signs of how it behaves in the body and against tumors.
-
ABBV-253 in adults with advanced solid tumors
This study tests ABBV-253 to see if it is safe, how it affects the cancer, and how the drug moves in the body for adults with advanced solid tumors.
-
MK-2010 alone or with other treatments for advanced solid tumors
This trial tests MK-2010, by itself or with other cancer medicines, to see if it helps people with advanced solid tumors.
-
Whole-Body Infrared Heating for Advanced Solid Tumors
This study looks at how ET-SPACE whole-body infrared hyperthermia affects people with advanced solid tumors to see if it changes biology, symptoms, and safety.
-
MK-2010 with Sac-TMT in advanced solid tumors
This study tests MK-2010 combined with sacituzumab tirumotecan (sac-TMT) to see if it can help people with advanced solid tumors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.